Press Release October 30, 2014

Goodwin Procter Represents 3 of the Top 10 Most Successful Biotech IPOs in 2014

Goodwin Procter attorneys represented drug developers SAGE Therapeutics, Zagfen and ProQR Therapeutics on three of the top ten most successful biotech IPOS in 2014, according to FierceBiotech.

SAGE Therapeutics’ initial public offering, which closed on July 23, sold 5,750,000 shares of common stock, including exercise of the over-allotment option in full, at $18 per share, the top end of its proposed range, raising $103.5 million before underwriting discounts and estimated offering expenses. SAGE’s shares began trading on the NASDAQ Global Market on July 18 under ticker symbol “SAGE.” Read more about the SAGE IPO.

Zafgen’s IPO closed on June 24, 2014 and sold 6,900,000 shares of common stock, including exercise of the over-allotment option in full, at $16 per share, the top end of its proposed range, before underwriting discounts and estimated offering expenses. Zafgen's shares began trading on the NASDAQ Global Market on June 25 under market ticker “ZFGN.” Read more about the Zagfen IPO.

ProQR Therapeutics’ initial public offering of 8,625,000 ordinary shares led to net proceeds of approximately $102 million. Shares priced at $13.00 per share and are traded on the Nasdaq Global Market under ticker symbol “PRQR.” Read more about the ProQR IPO.

Goodwin has one of the leading life sciences practices in the United States, and was named “Law Firm of the Year” in Biotechnology by U.S. NewsBest Lawyers for the last two consecutive years. The firm’s fully integrated practice, including corporate, intellectual property, partnering, regulatory and litigation attorneys, allows it to effectively serve clients at every stage of the company life cycle.